BIOG-B BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About BioGaia (STO: BIOG-B)
›
BioGaia (STO: BIOG-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 251 employees.
The shares were at 125.80 SEK on 19 November 2026, up 29.8% over 52 weeks. Its 52-week range is 96.20 SEK to 136.30 SEK: the price is 7.7% below the high and 30.8% above the low.
At a market capitalisation of 12.73B SEK, it trades at 32.5 times trailing earnings and 29.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 32% for BIOG-B. It pays a dividend yielding 1.31% (it pays out 42% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
BioGaia reports return on equity of 25.3%, an operating margin of 28.2% and revenue up 22.6% year over year.
It holds more cash than debt, a net cash position of 518.28M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 152.00 SEK is 20.8% above the current price. The next earnings report is expected on 12 February 2027.